PROVIDER NOTIFICATION OF RETAIL DRUG POLICY CRITERIA CHANGE			
Drug(s)Impacted	**CRITERIA CHANGE**	**EFFECTIVE DATE**	**Formulary**
Rasonque	New Criteria	11/1/2026	Standard
Bimzelx	New Criteria	1/1/2027	Metallic
Adbry	Adds initial-request documentation of affected areas and body surface area. Adds documentation or claims history of prerequisite therapies and responses. Adds continuation documentation of low disease activity or symptom improvement. Expands prescribing requirement to include consultation with an appropriate specialist. Removes flexural-lesion and groin/axillary-sparing documentation requirements. Expands severity eligibility to qualifying BSA, critical-area, IGA, EASI, or NRS criteria. Replaces tralokinumab with dupilumab in the prohibited combination examples. Adds continuation requirements for specialist oversight and prohibited combination therapy. Adds negative TB testing within six months before initiating therapy. Adds management requirements for positive, active, or latent TB findings. Expands concomitant-use prohibition to potent immunosuppressants, including azathioprine or cyclosporine.	1/1/2027	Standard
Dapagliflozin/metformin	Adds dapagliflozin/metformin to SGLT2 inhibitor/metformin target drugs	1/1/2027	Standard
Freestyle Libre 2	Adds FreeStyle Libre 2 quantity limits of 2 sensors/25 days and 6 sensors/75 days. Adds FreeStyle Libre 3 quantity limits of 2 sensors/25 days and 6 sensors/75 days.	1/1/2027	Metallic
Cibinqo	Adds initial-request documentation of affected areas and body surface area. Adds documentation or claims history of prerequisite therapies and responses. Adds continuation documentation of low disease activity or symptom improvement. Expands prescribing requirement to include consultation with an appropriate specialist.	01/01/2027	Standard

	Adds prohibition against biologic or targeted synthetic therapy for the same indication. Removes age-specific lesion and groin/axillary-sparing documentation requirements. Expands severity eligibility to qualifying BSA, critical-area, IGA, EASI, or NRS criteria.		
Dupixent	Expands CRSwNP eligibility to prior surgery or systemic corticosteroid failure. Removes age-specific lesion and groin/axillary-sparing requirements for atopic dermatitis. Expands atopic dermatitis severity eligibility to BSA, critical-area, IGA, EASI, or NRS criteria. Adds specialist oversight to atopic dermatitis continuation criteria.	01/01/2027	Standard and Metallic
Ebglyss	Removes age-specific lesion and groin/axillary-sparing documentation requirements. Expands severity eligibility to qualifying BSA, critical-area, IGA, EASI, or NRS criteria. Restricts topical therapy criteria by requiring both calcineurin inhibitor and corticosteroid failure. Expands prescribing requirement to include consultation with an appropriate specialist. Adds specialist oversight to continuation criteria. Adds negative TB testing within six months before initiating therapy. Adds management requirements for positive, active, or latent TB findings. Expands concomitant-use prohibition to potent immunosuppressants, including azathioprine or cyclosporine.	1/1/2027	Standard and Metallic
Nemluvio	New Criteria	1/1/2027	Standard and Metallic
Nucala	Adds documentation requirements for asthma, CRSwNP, COPD, EGPA, and HES. Adds EGPA prescriber specialties: allergist/immunologist, pulmonologist, or rheumatologist. Adds HES prescriber specialties: allergist/immunologist, hematologist, or cardiologist. Expands CRSwNP eligibility to prior surgery/non-candidacy or systemic corticosteroid failure.	1/1/2027	Standard and Metallic
Rezdiffra	New Criteria	1/1/2027	Standard and Metallic

Rinvoq	Adds initial and continuation documentation requirements for atopic dermatitis. Removes age-specific lesion and groin/axillary-sparing documentation requirements. Expands severity eligibility to BSA, critical-area, IGA, EASI, or NRS criteria. Expands specialist oversight to include prescribing or consultation.	1/1/2027	Standard and Metallic
Tezspire	Adds documentation requirements for asthma and CRSwNP. Adds prescriber specialty requirements by indication. Adds CRSwNP initial and continuation coverage criteria. Adds continuation requirement for maintenance asthma treatments. Adds prohibition against concomitant biologic or targeted synthetic therapy. Adds smoking and vaping cessation counseling guidance.	1/1/2027	Standard
Xolair	Adds documentation requirements for asthma, CRSwNP, CSU, and IgE-mediated food allergy. Adds prescriber specialty requirements by indication. Adds smoking and vaping cessation counseling guidance. Adds asthma continuation requirements for specialist oversight and prohibited combination therapy. Expands CRSwNP eligibility to prior surgery/non-candidacy or systemic corticosteroid failure. Adds IgE-mediated food allergy requirements for prohibited combination therapy. Adds FDA-label dosing requirements for IgE-mediated food allergy. Adds specialist oversight requirements for IgE-mediated food allergy.	1/1/2027	Standard and Metallic
Sohonos	1) Added criteria to initial coverage and continuation of therapy that member will not use in combination with Pasatru. 2) Updated initial coverage and continuation of therapy criteria to require females of reproductive potential to have a negative pregnancy test, and that member is not currently breastfeeding, pregnant, or planning pregnancy, as per FDA approved label.	12/9/2026	Standard and Essential

	3) Updated initial coverage criteria to require member not to have any significant comorbid illness, as per pivotal clinical trial. 4) Updated continuation of therapy criteria to require that the member has not had any serious adverse event that would contraindicate continued therapy, as per FDA-approved label.		
Imaavy	Added coverage for warm autoimmune hemolytic anemia per label update.	11/1/2026	Standard and Essential
Evkeeza	In the coverage criteria, updated the LDL-C level to greater than or equal to 100 mg/dL per 2026 ACC/AHA dyslipidemia guidelines.	12/16/2026	Standard and Essential
Juxtapid	In the coverage criteria, updated the LDL-C level to greater than or equal to 100 mg/dL per 2026 ACC/AHA dyslipidemia guidelines.	12/16/2026	Essential
Redemplo	Added clinical features criteria to the diagnostic requirements for familial chylomicronemia syndrome (FCS).	12/16/2026	Standard and Essential
Tryngolza	1) Added clinical features criteria to the diagnostic requirements for familial chylomicronemia syndrome (FCS). 2) Added coverage for severe hypertriglyceridemia (sHTG) per FDA label update.	12/16/2026	Standard and Essential
Blenrep	For multiple myeloma, added coverage for use in combination with dexamethasone and either pomalidomide or carfilzomib after at least one prior line of therapy, added coverage for progression after B-cell maturation antigen therapy, per NCCN. For POEMS syndrome, MIDD, and MGRS, removed regimen specifications to align with other criteria for these indications. Added coverage for systemic light chain amyloidosis, per NCCN.	11/8/2026	Standard and Essential
Xpovio	For multiple myeloma, added coverage for myeloma with central nervous system disease, removed requirement that the member must be refractory to two proteasome inhibitors, immunomodulatory agents, and an anti-CD38 monoclonal antibody, reduced the number of prior lines of therapy received from four to three when used in combination with dexamethasone, added coverage for progression after B-cell maturation antigen therapy, per NCCN.	11/8/2026	Standard and Essential

	For B-cell lymphomas, expanded coverage for histologic transformation of indolent lymphomas to diffuse large B-cell lymphoma, per NCCN. Added coverage for polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes (POEMS) syndrome, plasma cell-related monoclonal immunoglobulin deposition disease (MIDD) and plasma cell-related monoclonal gammopathy of renal significance (MGRS), per NCCN.		
Ibrance	Added coverage for use in combination with Etcamah (camizestrant) for breast cancer, per Etcamah FDA label update.	11/8/2026	Standard and Essential
Kisqali	Added coverage for use in combination with Etcamah (camizestrant) for breast cancer, per Etcamah FDA label update.	11/8/2026	Standard, Metallic and Essential
Verzenio	Added coverage for use in combination Inluriyo (imlunestrant) for breast cancer, per NCCN and FDA label update. Added coverage for use in combination with Etcamah (camizestrant) for breast cancer, per Etcamah FDA label update.	11/8/2026	Standard, Metallic and Essential
Redemplo	Added clinical features criteria to the diagnostic requirements for familial chylomicronemia syndrome (FCS).	11/8/2026	Standard and Essential
Joenja	1) Added age requirement to continuation of therapy, per FDA label. 2) Updated the age and weight requirement for 4 years of age or older who weigh 27 kg or greater in Coverage Criteria, per FDA label.	12/23/2026	Standard and Essential